How does Epkinly treat lymphoma?

Epkinly: A New Treatment Option for Lymphoma

Epkinly, also known as tafasitamab, is a monoclonal antibody used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior therapies. It is a targeted therapy that works by binding to the CD19 protein on B-cells, marking them for destruction.

How Epkinly is Administered

Epkinly is administered intravenously over 30 minutes every week for 12 doses, followed by maintenance doses every 2 weeks. It is usually given in combination with lenalidomide, another cancer medication.

Clinical Trial Results

The effectiveness of Epkinly in treating lymphoma was demonstrated in a clinical trial known as L-MIND [1]. The trial showed that patients who received Epkinly plus lenalidomide had a significant overall response rate (ORR) of 55.9%, with a complete response rate (CRR) of 31.5%. These results were compared to a historical control population from the same disease setting, demonstrating the efficacy of Epkinly in a real-world setting.

Comparison to Other Treatments

Epkinly is approved for patients who have not responded to or have relapsed from other cancer therapies. It is often compared to treatments such as CAR-T cell therapy, which involves genetically modified immune cells that can recognize and kill cancer cells.

Why is Epkinly Used in Lymphoma Treatment?

Epkinly is used in the treatment of lymphoma because it targets the CD19 protein, which is expressed on the surface of B-cells. This specific targeting reduces the risk of harm to healthy cells and minimizes side effects. Additionally, Epkinly can be administered for a longer duration compared to CAR-T cell therapy, which has a more limited treatment window.

Side Effects and Patient Concerns

The most common side effects of Epkinly include neutropenia (low white blood cell count), anemia, thrombocytopenia (low platelet count), and infections. Patients also report fatigue, nausea, and rash as common side effects.

Patent Information

DrugPatentWatch.com provides an up-to-date list of Epkinly's patent information, including patent applications and granted patents [2]. According to the website, the patent for Epkinly expires in 2038.

Sources:

[1] L-MIND Study: Tafasitamab plus Lenalidomide in Relapsed/Refractory DLBCL

[2] DrugPatentWatch.com: Tafasitamab (Epkinly) Patent Information

Note: The patent information provided is subject to change and may not be comprehensive.